Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 83 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2014', provides an overview of the Ventilator Associated Pneumonia (VAP)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ventilator Associated Pneumonia (VAP) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ventilator Associated Pneumonia (VAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ventilator Associated Pneumonia (VAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ventilator Associated Pneumonia (VAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ventilator Associated Pneumonia (VAP) Overview 8
Therapeutics Development 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 10
Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 11
Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 13
Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 17
Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 18
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
Cubist Pharmaceuticals, Inc. 20
Paratek Pharmaceuticals, Inc. 21
KaloBios Pharmaceuticals, Inc. 22
Tetraphase Pharmaceuticals Inc. 23
Savara Inc. 24
Cardeas Pharma Corp. 25
Meiji Seika Pharma Co., Ltd. 26
Adenium Biotech ApS 27
Serendex Pharmaceuticals A/S 28
Dong-A Socio Group 29
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
tedizolid phosphate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(ceftolozane + tazobactam) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(ceftazidime + avibactam) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
eravacycline - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(amikacin + fosfomycin) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
KB-001A - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
arbekacin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule for Infectious Diseases - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
vancomycin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
pseudomonas and VAP conjugate vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Pseudomonas aeruginosa Vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AA-139 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
fosfomycin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
sargramostim - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Ventilator Associated Pneumonia (VAP) - Recent Pipeline Updates 60
Ventilator Associated Pneumonia (VAP) - Dormant Projects 78
Ventilator Associated Pneumonia (VAP) - Discontinued Products 79
Ventilator Associated Pneumonia (VAP) - Product Development Milestones 80
Featured News & Press Releases 80
Jun 21, 2013: Theravance Gets FDA Approval For Vibativ For Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia 80
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2014 9
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca PLC, H2 2014 19
Ventilator Associated Pneumonia (VAP) - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 20
Ventilator Associated Pneumonia (VAP) - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 21
Ventilator Associated Pneumonia (VAP) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2014 22
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 23
Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H2 2014 24
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H2 2014 25
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2014 26
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H2 2014 27
Ventilator Associated Pneumonia (VAP) - Pipeline by Serendex Pharmaceuticals A/S, H2 2014 28
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Group, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Assessment by Combination Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Ventilator Associated Pneumonia (VAP) Therapeutics - Recent Pipeline Updates, H2 2014 60
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2014 78
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H2 2014 79